Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Analysts at B. Riley issued their FY2017 earnings per share estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday. B. Riley analyst M. Kumar forecasts that the biopharmaceutical company will post earnings per share of ($0.59) for the year. B. Riley has a “Neutral” rating and a $3.50 price target on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2018 earnings at ($0.67) EPS, FY2019 earnings at ($0.74) EPS, FY2020 earnings at ($0.75) EPS, FY2021 earnings at ($0.67) EPS and FY2022 earnings at ($0.65) EPS.
Several other research firms have also recently weighed in on ACHN. Leerink Swann reaffirmed a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Finally, Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $4.89.
In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.24% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas bought a new position in Achillion Pharmaceuticals during the fourth quarter valued at $109,000. Bourgeon Capital Management LLC lifted its position in Achillion Pharmaceuticals by 64.4% during the fourth quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 19,004 shares during the last quarter. SG Americas Securities LLC lifted its position in Achillion Pharmaceuticals by 59.8% during the third quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 15,800 shares during the last quarter. Voya Investment Management LLC lifted its position in Achillion Pharmaceuticals by 13.7% during the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 6,730 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in Achillion Pharmaceuticals by 18.6% during the second quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 76.78% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.